Therapeutic Class Indications Effective

Transcription

1 Mortar & Pestle A Publication of Walgreens Health Initiatives July 30, 2009 A publication created especially for our clients and associates, delivering up-to-date information about brand-name and generic, medical products, and other pharmaceutical-related information collected from key government and industry sources. Products Added to the PML Brand Baraclude tablets Generic entecavir Antiviral Effective Rationale Date 08/15/09 The American Association for the Study of Liver Disease (AASLD) recommends Baraclude as a first-line for treatment-naïve patients and treatment-experienced chronic hepatitis B patients. Clinical trials demonstrate safety and efficacy over other s in this class. Other Changes to the PML Brand Adcirca tablets Generic tadalafil Indications Effective Date Description of Change Pulmonary arterial PAH (WHO Group 08/10/09 Added to Specialty PBM list. hypertension (PAH) I) to improve exercise ability The accuracy and completeness of the content herein are not guaranteed by Walgreen Co. or its affiliates and subsidiaries. Content not to be construed as a solicitation or recommendation. Brand names are the property of their respective owners Walgreens Health Initiatives. All rights reserved. 1

2 Recent Food and Drug Administration (FDA) warnings and health news for patients and healthcare professionals Drug/Issue Date News Event(s) Member/Client Impact Strategic Rationale Action Needed to Implement New Products* Drug/Manufacturer Acuvail (ketorolac) 0.45% ophthalmic solution/allergan Onsolis (fentanyl) buccal soluble film/meda Ophthalmic Narcotic analgesic New FDA-Approved Agents New Dosage Forms and Combinations pain 07/22/09 Unknown Preservative-free and inflammation formulation of ketorolac following cataract Contains surgery carboxymethylcellulose, which allows the drug to adhere to the ocular surface and enhances breakthrough cancer pain 07/16/09 Fourth quarter of 2009 comfort Small, dissolvable polymer film for application to the inner lining of the cheek update lists as needed. Will evaluate for a program when available. 2

3 Sumavel DosePro (sumatriptan) injection/ Zogenix Forteo (teriparatide [rdna origin]) injection/lilly Antimigraine Osteoporosis migraine and cluster headache 07/15/09 Unknown Needle-free delivery system to treat cluster headache and acute migraine with or without aura New FDA-Approved Indications osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture 07/22/09 Available Forteo is also indicated for treatment of postmenopausal women with osteoporosis and to increase bone mass in men with primary or hypogonadal osteoporosis. update conflict edits and lists as needed. Migraine CPA available. Clients update lists as needed. Forteo is preferred. No changes review for conflict edit and list updates. Osteoporosis 3

4 Tekturna HCT (aliskiren/ hydrochlorothiazide) tablets/novartis Tri-Lo-Sprintec (ethinyl estradiol/ norgestimate) tablets/ Teva Antihypertensive Oral contraceptive Initial treatment of hypertension in patients who are likely to require multiple s to achieve goal 07/16/09 Available Combination of Tekturna, a direct renin inhibitor, with a thiazide diuretic New First-Time Generic Drug Approvals Prevention of 06/29/09 TBD Initially launched on pregnancy 07/01/09 but ceased on 07/07/09. Teva and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of Ortho Tri- Cyclen Lo, until the Court's ruling on the motion for preliminary Forteo SPA in place. Clients Tekturna HCT is preferred. No changes review for conflict edit and list updates. Generic products remaining on the market may be dispensed and are available on lowest copay tier. Contraceptives CPA available. 4

5 * Note: If FDA-approved, s are under P&T review and reside on the third tier. injunction or 07/29/09, whichever is earlier. Clients Pipeline Analysis Drug/Manufacturer Indication(s) Status First-Time Generic Drugs in the Pipeline Information for Mortar & Pestle is compiled by Walgreens Clinical Information Services and obtained from the following sources (with secondary-source links provided): Food and Drug Administration ( American Society of Health-System Pharmacists ( P&T Community ( Pharmaceutical News Harvest ( Drugs.com ( Pharmacy OneSource ( 5